MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.65
-0.23
-3.34%
Opening 09:45 10/30 EDT
OPEN
6.87
PREV CLOSE
6.88
HIGH
6.87
LOW
6.61
VOLUME
7.80K
TURNOVER
--
52 WEEK HIGH
14.69
52 WEEK LOW
4.260
MARKET CAP
304.32M
P/E (TTM)
-3.9242
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update.
Business Wire · 1d ago
Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Are Down 60% On Their Shares
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have...
Simply Wall St. · 2d ago
Syros's SY-5609 shows encouraging action in early-stage solid tumor study
Syros Pharmaceuticals (SYRS) has announced initial safety, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) data from dose-escalating part of its Phase 1 trial of SY-5609 in patients with select solid tumors. Data are being
Seekingalpha · 4d ago
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose (MTD) for continuous daily dosing. The data are being presented in a poster session at the 32nd EORTC-NCI-AACR Symposium.
Business Wire · 6d ago
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 10/18 16:50
Piper Sandler: These 2 Healthcare Stocks Could Be the Next M&A Target
Who’s next? After Gilead snapped up Immunomedics for $21 billion in September, gaining access to Trodelvy, an antibody conjugate that could be used in triple negative breast cancer, as a result, investors want to know which name looks like the next M&A target.Piper Sandler analyst Christopher Raymond points to oncology companies as the “easy answer,” based on how hot the space has been over the last few years. “While even the most casual biotech observer is likely to have some level of awareness around M&A as a key theme in the space, it’s also fairly clear that oncology as a subsector has seen an outsized share of M&A activity. Reasons for this would appear to be fairly obvious as the confluence of a highly fragmented therapeutic space, massive unmet medical need, and significant innovation have contributed to significant demand on the part of buyers,” wrote.Going off of BIO's analysis of global acquisition activity from 2009 to 2018, Raymond found that oncology continued to be the dominant therapeutic area for M&A activity in 2019, with nine completed deals valued at over $34.4 billion combined, more than doubling from 2018.With this in mind, we wanted to take a closer look at two healthcare stocks that could be M&A targets, according to Piper Sandler. Using TipRanks’ database, we did a deep dive into the data to find out what makes both so attractive.Syros Pharmaceuticals (SYRS)Developing gene control-based therapies, Syros Pharmaceuticals wants to stomp out cancer for good. Ahead of the upcoming data readouts for its candidates, Piper Sandler believes now is the time to pull the trigger before it potentially gets bought up.SYRS remains on track to release data for SY-1425, which was designed as an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist for use in AML patients.Representing Piper Sandler, 5-star analyst Edward Tenthoff points out that the encouraging data for SY-1425 makes SYRS a likely M&A target. Based on available data, SY-1425 combined with azacitidine produced a 62% CR/CRi rate in 8 out of 13 RARα-positive AML patients, compared to only 27% in 6 of 22 RARα-negative patients.“Data continues to highlight the importance of the RARα biomarker, expressed in ~30% of all AML patients. Importantly, SY-1425 has been safe with no neutropenia often observed with HMA and azacitidine combination,” Tenthoff stated. Syros has completed enrollment, and is set to report r/r AML RARα-positive data in Q4 2020, most likely at ASH, according to the analyst.To this end, Tenthoff rates SYRS an Overweight (i.e. Buy) along with an $18 price target. Investors could be pocketing a gain of 112%, should this target be met in the twelve months ahead. (To watch Tenthoff’s track record, click here)Overall, with 3 Buys and 2 Holds assigned in the last three months, the word on the Street is that SYRS is a Moderate Buy. At $14.40, the average price target implies 64% upside potential from current levels. (See SYRS stock analysis on TipRanks)TCR2 Therapeutics (TCRR)Using its patented TRuC (TCR Fusion Construct) T cells, TCR2 Therapeutics harnesses the natural T cell receptor complex to recognize and kill cancer cells. Given its innovative cell therapy platform, Piper Sandler thinks it could get picked up by another healthcare player.Firm analyst Tyler Van Buren tells clients “clinical success in solid tumors with cell therapy has largely been elusive,” but that changed when TCRR reported initial clinical data for TC-210, its most advanced TRuC-T cell product candidate, in mesothelin positive tumors. Calling the results encouraging, the analyst notes all five patients achieved tumor reductions (2 uPRs) after a single infusion of TC-210 TRuC-T cells at the first dose level.“This data provides validation for the TRuC-T cell platform, which incorporates the best elements from both CAR-Ts and TCR-Ts, and could overcome the limitations of current generation products... TC-210 could have accelerated opportunities in mesothelioma and cholangiocarcinoma, with additional larger opportunities in lung and ovarian,” Van Buren commented.Additionally, Van Buren argues this data indicates clear monotherapy activity in solid tumors. Even though the patient numbers were small, the initial 50% response rate in third line-plus mesothelioma patients is better than chemo and immuno-oncology (IO) in the second line (10-20%) and third line-plus (single-digit RR) settings. 1 out of 2 responders is eligible for confirmation, which could come soon, according to the analyst.What’s more, initial durability appears to be solid, especially given that two patients have been on study for over six months. Van Buren added, “One ovarian cancer patient is also on study and currently has stable disease with the potential to respond. In terms of safety, TC-210 appears manageable and no on-target/off-tumor toxicities have been observed.” Ahead of the update on four of the patients reported so far (3 mesothelioma, 1 ovarian), as well as initial data on an additional seven or more patients, he thinks the therapy represents a $2.5 billion-plus opportunity by 2035.In line with his optimistic approach, Van Buren rates TCRR an Overweight (i.e. Buy) along with a $35 price target. This figure implies a 72% upside from current levels. (To watch Van Buren’s track record, click here)There’s not much dissent to Van Buren's thesis amongst his colleagues. TCRR's Strong Buy consensus rating is backed by 7 Buys. The average price target stands at $33.14, and implies possible upside of 60%.(See TCRR stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 10/15 18:38
Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the ongoing
Benzinga · 10/09 11:33
Who Has Been Buying Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Simply Wall St. · 09/10 19:47
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYRS. Analyze the recent business situations of Syros Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYRS stock price target is 15.71 with a high estimate of 20.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 105
Institutional Holdings: 46.47M
% Owned: 101.54%
Shares Outstanding: 45.76M
TypeInstitutionsShares
Increased
36
4.69M
New
25
-485.21K
Decreased
16
4.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.23%
Pharmaceuticals & Medical Research
-0.52%
Key Executives
Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Nancy Simonian
Chief Financial Officer
Joseph Ferra
Chief Scientific Officer
Eric Olson
Chief Accounting Officer
Colleen DeSimone
Other
Gerald Quirk
Other
David Roth
Other
Jeremy Springhorn
Director
S. Gail Eckhardt
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.